Evidence mapPaperPMID 31504452Full record

ArticleEuropean heart journal2019

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, Alan G Fraser, Stefan D Anker, Erwan Donal, Frank Edelmann, Michael Fu, Marco Guazzi, Carolyn S P Lam and 14 more

Erratum issued 5 registry-linked trialsOpen access · bronzeAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in European heart journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 5 registered trials, which are not on this map. Cited by 793 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
793citing papers in PubMed, 3 pooled it
118.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06249945 phase4recruitingstarted 2024, after this paper: background citation

The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Preserved Ejection Fraction - a Randomized Controlled Trial

Ran2024Enrolled150Registered outcomes27Posted comparisons0ConditionsEnd Stage Renal Disease on Dialysis, Heart Failure With Preserved Ejection FractionArmsempagliflozin 25 mg, Placebo
Open the trial in the graph
NCT04395846 active not recruitingnot on this mapstarted 2020, after this paper: background citation

Heart Failure and Preserved Ejection Fraction: Observation of Its Progression and Prognosis (HOPP-BERN)

TypeobservationalSponsorInsel Gruppe AG, University Hospital BernRan2020 to 2029Enrolled350ConditionsHeart Failure With Preserved Ejection Fraction
NCT04970953 terminatednot on this mapstarted 2021, after this paper: background citation

Prospective Analysis of Diastolic Stress Tests to Detect Exercise Induced Heart Failure With Preserved Ejection Fraction (HFpEF) in Patients With Intermediate Risk (DEST-HF Study, Diastolic Exercise Stress Testing in Heart Failure)

TypeobservationalSponsorUniversity Hospital, EssenRan2021 to 2023Enrolled19ConditionsHeart Failure With Preserved Ejection FractionArmsRight heart catheterization
NCT07429396 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Data-Driven Phenotyping in Heart Failure With Preserved Ejection Fraction

TypeobservationalSponsorInstituto Politécnico de LeiriaRan2026 to 2028Enrolled200ConditionsHeart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction (HFPEF)
NCT07481825 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Impact of Combined cARdio-pUlmonary aSsessment on COPD Clinical Management: the ICARUS Study

TypeinterventionalSponsorUniversity of Bari Aldo MoroRan2026 to 2029Enrolled350ConditionsCOPD (Chronic Obstructive Pulmonary Disease), Cardiovascular DiseaseArmsStructured combined cardio-pulmonary clinical management strategy, Standard Respiratory Management
3 · Its place in the literature

Who cites it

793 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,712 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

733 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 19 institutions in 15 countries.

Burkert PieskeDepartment of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum.
Carsten TschöpeDepartment of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum.
Rudolf A de BoerUniversity Medical Centre Groningen, University of Groningen, Department of Cardiology, Groningen, the Netherlands.
Alan G FraserSchool of Medicine, Cardiff University, Cardiff, UK.
Stefan D AnkerDepartment of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum.
Erwan DonalCardiology and CIC, IT1414, CHU de Rennes LTSI, Université Rennes-1, INSERM 1099, Rennes, France.
Frank EdelmannDepartment of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum.
Michael FuSection of Cardiology, Department of Medicine, Sahlgrenska University Hosptal/Ostra, Göteborg, Sweden.
Marco GuazziDepartment of Biomedical Sciences for Health, University of Milan, IRCCS, Milan, Italy.
Carolyn S P LamNational Heart Centre, Singapore & Duke-National University of Singapore.
Patrizio LancellottiDepartment of Cardiology, Heart Valve Clinic, University of Liège Hospital, GIGA Cardiovascular Sciences, CHU Sart Tilman, Liège, Belgium.
Vojtech MelenovskyInstitute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
Daniel A MorrisDepartment of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum.
Eike NagelInstitute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt.
Elisabeth Pieske-KraigherDepartment of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum.
Piotr PonikowskiMedical University, Clinical Military Hospital, Wroclaw, Poland.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ramachandran S VasanSection of Preventive Medicine and Epidemiology and Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Frans H RuttenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Adriaan A VoorsUniversity Medical Centre Groningen, University of Groningen, Department of Cardiology, Groningen, the Netherlands.
Frank RuschitzkaUniversity Heart Centre, University Hospital Zurich, Switzerland.
Walter J PaulusDepartment of Physiology and Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, The Netherlands.
Petar SeferovicUniversity of Belgrade School of Medicine, Belgrade University Medical Center, Serbia.
Gerasimos FilippatosDepartment of Cardiology, National and Kapodistrian University of Athens Medical School; University Hospital "Attikon", Athens, Greece.
German Centre for Cardiovascular Research · DEUniversity Medical Center Groningen · NLCharité - Universitätsmedizin Berlin · DEAmsterdam University Medical Centers · NLBoston University · USBrigham and Women's Hospital · USCardiff University · GBGoethe University Frankfurt · DEInserm · FRInstitute of Clinical and Experimental Medicine · CZNational and Kapodistrian University of Athens · GRSahlgrenska University Hospital · SEUniversitätsmedizin Göttingen · DEUniversity Hospital of Zurich · CHUniversity of Belgrade · RSUniversity of Liège · BEUniversity of Milan · ITUtrecht University · NLWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e'), left ventricular (LV) filling pressure estimated using E/e', left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.

Indexed as

AlgorithmsClinical Decision-MakingAgedCardiologyEchocardiographyFemaleHeart Failure, DiastolicHeart VentriclesHumansMaleMiddle AgedNatriuretic PeptidesPractice Guidelines as TopicNatriuretic Peptidesbiomarkersdiagnosisechocardiographyexercise echocardiographyHeart failureHFpEFnatriuretic peptides

Identifiers

PMID31504452
OpenAlexW2971111962

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.